PharmaCyte Biotech, Inc. has announced a 1-for-19 reverse stock split of its common stock, which became effective at 4:01 p.m. Eastern Time on November 12, 2026. The split was approved by the company’s board of directors and stockholders at the annual meeting held on March 30, 2026. The filing with the Nevada Secretary of State details that the reverse split will reduce the number of issued and outstanding shares from approximately 10,755,649 shares as of November 11, 2026, to about 566,087 shares.
Under the terms of the reverse split, every nineteen (19) shares of the company’s common stock will be automatically combined into one (1) share. The par value per share remains unchanged at $0.0001. The company stated that the split is intended to increase the per share trading price to help the company regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
Trading on a split-adjusted basis began at the open of the market on November 13, 2026. The company’s common stock continues to trade under the ticker symbol "PMCB" on The Nasdaq Capital Market. A new CUSIP number, 71715X302, has been assigned to the stock following the split. No change was made to the total number of shares authorized under the company’s Articles of Incorporation.
Proportional adjustments have been made to the per share exercise price and the number of shares issuable upon the exercise of all outstanding stock options, warrants, and convertible securities. Additionally, adjustments were made to the number of shares issued and issuable under the company’s equity incentive plans. Any stockholder entitled to a fractional share as a result of the split will receive a cash payment equal to the fractional share multiplied by the closing sales price of the stock on the trading day immediately prior to the effective time.
